Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

CHASE LABS' NIFEDIPINE CITED BY FDA FOR DISSOLUTION FAILURE

Executive Summary

CHASE LABS' NIFEDIPINE CITED BY FDA FOR DISSOLUTION FAILURE in a Dec. 5 warning letter. An Aug. 8 inspection of Chase's Newark, N.J. oral dosage form drug manufacturing facility by FDA revealed "inadequate investigation and documentation of the failure of nifedipine capsules to meet USP XXII dissolution requirements," the letter says. FDA also observed Chase's "failure to validate and document drying times and temperatures for soft gelatin capsules" of the generic calcium channel blocker. FDA's Newark District Office said that no recalls have been initiated in connection with the warning letter. Chase Labs President Richard Remaly indicated that no lots were ever shipped for retail sale in the U.S. that did not pass dissolution testing. Chase met with FDA on Dec. 19 and responded to FDA's Form 483 inspection report on Nov. 14. While the agency called that reply "responsive" in its warning letter, it added that "some questions still remain open." Not enough lots of nifedipine were retested for dissolution, the letter states. Concerning the capsule drying time specifications, "no prospective validation study has been committed to," FDA said. FDA's Newark District Office recommended to the Center for Drug Evaluation and Research that approval of two pending Chase ANDAs be withheld until "all issues pertaining to capsule drying time validation have been addressed and it is certified in writing by [the company] that appropriate corrections have been made," the letter states. The letter also notes that "several" batches of nifedipine 10 mg capsules that failed dissolution specifications were introduced into interstate commerce. The capsules were distributed to charity, which, the letter notes, "has no bearing on their legal status." Chase received the first generic approval for nifedipine 10 mg soft gels in September 1990 after successfully challenging Pfizer's Procardia patent ("The Pink Sheet" Sept. 10, 1990, p. 7).

You may also be interested in...



Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance

FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials

Shire Hopes To Sow Future Deals With $50M Venture Fund

Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth

UsernamePublicRestriction

Register

OM006665

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel